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Recent advances in genetic engineering has made it possible to prepare large amounts 
of antibodies, to humanize them, and to make their size small. Since molecular biology of 
cancer rapidly progressed, cancer treatment is shifting to molecular targeted therapy with an 
antibody specific for antigen of cancer cells. As a result, development of a molecular imaging 
technique of the therapeutic target has become important. For example, an antibody type 
diagnostic probe can be used for monitoring in the course of treatment by the immunotherapy 
with an antibody. Therefore, we have tried to develop a novel method for preparation of 
positron-emitter labeled antibody by using cell-free protein synthesis (CFPS) system (1). The 
method is to synthesize an antibody in vitro by using enzymes, several factors, template 
mRNA, natural amino acids, and a positron-emitter labeled amino acid (Fig. 1). In this study, 
we prepared and biologically evaluated a 11C-labeled single chain antibody (scFv) to HER2 
which is a transmembrane protein receptor with tyrosine kinase activity and overexpressed in 
breast and stomach cancers. HER2 is used as a prognostic factor for breast cancer diagnosis 
and a predictor of therapeutic effect. That is, HER2 positive breast cancer has poor prognosis 
and anti-HER2 therapy responds well. HER2-PET would be applicable to imaging 
biomarkers for diagnosis and therapy monitoring of breast cancer. 
 
Methods 
In this study, a single chain antibody of trastuzumab (tra-scFv) which bind strongly to 
HER2 was prepared by using CFPS system (Musaibo-Kun®) and 11C-methionine as a part of 
amino acid sources for protein synthesis. To the kit solution of CFPS system, template DNA 
(plasmid) and 11C-methionine (ca 1400 MBq/mL in saline) were added and incubated at 37℃. 
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After the incubation, 11C-tra-scFv was purified by immune-affinity chromatography. 
Radiochemical yields was determined by SDS-PAGE and autoradiography (ARG). Binding 
affinity of 11C-tra-scFv to HER2 was assessed by cell-biding assay using SK-OV-3 (human 
ovarian cancer cells with high expression of HER2) and MCF7 (human breast cancer cells 
with low expression of HER2). The tissue uptake of the tracer was evaluated by 
biodistribution study and small animal PET imaging.  
 
Results and Discussion 
Decay-corrected radiochemical yields of 11C-tra-scFv were 8.6~13%. The binding 
rates (%ID/106 cells) of 11C-tra-scFv were 15.8 ± 0.6 %ID/106 cells and 2.2 ± 0.2 %ID/106 
cells for SK-OV-3 and MCF7, respectively (Fig. 2). The binding to SK-OV-3 was strongly 
inhibited by addition of trastuzumab, suggesting the specific binding of 11C-tra-scFv to HER2 
molecule. Biodistribution study in normal mice (ICR mice) demonstrated that 11C-tra-scFv 
accumulated mainly in the kidney at 30 min and 60 min post-injection (Fig. 3). This 
biodistribution was also confirmed by PET imaging. These data indicate that the injected 11C-
tra-scFv shows smooth clearance from the body through kidney. This feature is necessary to 
obtain PET images of the thoracic region with low radioactivity background. Actually, when 
11C-tra-scFv was injected into a tumor bearing mouse made by implantation of SK-OV-3 cells 
to flank, the tumor was clearly visualized by PET (Fig. 4). Moreover, 11C-tra-scFv showed 
high binding to the tumor tissue sections of SK-OV-3 in vitro, and the binding was completely 
blocked by addition of trastuzumab. These findings indicate that 11C-tra-scFv can specifically 
bind to HER2 molecule expressed in the tumor tissue. 
 
Conclusion 
Using cell-free protein synthesis system and 11C-methionin, we succeeded to prepare 
11C-labeled a single chain antibody which shows high binding to the antigen molecule. This 
study demonstrated that 11C-tra-scFv synthesized by this method could be useful as a PET 
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Figure 2. Cell binding assay for evaluation of binding of 11C-tra-scFv to HER2 
using SK-OV-3 (human ovarian cancer cells with high expression of HER2) and 








Figure 4.  Tumor imaging by PET with 11C-tra-scFv. 
